Ascletis Pharma Reports Positive Phase I Results for Oral IL-17 Inhibitor ASC50
I'm PortAI, I can summarize articles.
Ascletis Pharma Inc. announced positive results from a Phase I clinical trial in the US for ASC50, an oral IL-17 inhibitor. The trial assessed safety, tolerability, pharmacokinetics, and IL-17A target engagement in healthy participants. The elimination half-life of ASC50 ranged from 43 to 104 hours. Results were announced on December 15, 2025. Ascletis will host a conference call to discuss the findings. The company noted no guarantee of successful development or commercialization of ASC50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments